Shares of Accelerate Diagnostics Inc. (NASDAQ:AXDX) shot up 2.8% during mid-day trading on Friday . The stock traded as high as $20.64 and last traded at $20.44, with a volume of 101,988 shares trading hands. The stock had previously closed at $19.88.

Several research firms recently issued reports on AXDX. JPMorgan Chase & Co. began coverage on shares of Accelerate Diagnostics in a report on Thursday, March 24th. They issued an “overweight” rating and a $17.00 price target on the stock. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Accelerate Diagnostics in a report on Monday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $26.00 price target on shares of Accelerate Diagnostics in a report on Sunday, May 15th. Finally, Zacks Investment Research cut shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, July 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $22.67.

The firm’s market cap is $1.05 billion. The firm has a 50 day moving average price of $16.28 and a 200 day moving average price of $14.19.

In related news, Director Jack W. Schuler purchased 20,000 shares of the stock in a transaction on Friday, May 13th. The shares were bought at an average price of $12.45 per share, for a total transaction of $249,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jack W. Schuler purchased 4,270 shares of the stock in a transaction on Friday, May 20th. The shares were bought at an average price of $11.04 per share, for a total transaction of $47,140.80. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Accelerate Diagnostics stock. Tekla Capital Management LLC boosted its stake in Accelerate Diagnostics Inc. (NASDAQ:AXDX) by 83.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 264,625 shares of the company’s stock after buying an additional 120,000 shares during the period. Tekla Capital Management LLC owned 0.59% of Accelerate Diagnostics worth $5,687,000 as of its most recent SEC filing.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.